Epstein–Barr virus‐positive plasmacytoma in immunocompetent patients

Abstract

We suggest the term EBV-positive plasmacytoma in immunocompetent patients for these lesions. It is essential to distinguish these tumours from plasmablastic lymphoma, as the latter diagnosis is associated with a much poorer prognosis, and patients require much more aggressive therapy.

Multidetector Computed Tomography Features of Plasmablastic Lymphoma of the Oral Cavity in an HIV-Positive Patient

“…Plasmablastic plasmacytoma is inactive neoplasm and most likely localized [13]. It lacks a starry sky pattern and has low rate of Ki67 index [13].…”

“…It lacks a starry sky pattern and has low rate of Ki67 index [13]. Patients with this neoplasm have responded well to radiation therapy and/ or chemotherapy [13].…”

“…It lacks a starry sky pattern and has low rate of Ki67 index [13]. Patients with this neoplasm have responded well to radiation therapy and/ or chemotherapy [13]. Positive CD20 and CD45 immunoreactivity exclude immunoblastic DLBCL from the differential diagnosis [5].…”

An immunocompetent patient with a recurrence-free Epstein-Barr virus positive plasmacytoma possesses robust Epstein-Barr virus specific T-cell responses

“…We found a significant population of immune infiltrates that were in close proximity to EBER + + cells had disease-free survival, however, this study did not examine EBV-specific responses. 13 We propose that tumor removal and subsequent local radiotherapy, together with the presence of strong EBV-specific T-cell responses, are responsible for the current healthy status of the patient, and that examining EBV-specific T-cell responses might be informative for future prognoses. …”

“…+ tumor infiltrates. 13 Interestingly, while they proposed that the infiltrating CD8 + T cells might result in favorable patient outcomes, they did not assess EBV-specific T-cell reactivity. We have now identified an immunocompetent individual with an EBV + plasmacytoma whose tumor and PBMCs have been examined using immunohistochemistry and for EBV-specific T-cell reactivity, respectively, and who continues to be recurrence-free.…”